To estimate the cost-effectiveness of faecal occult blood (FOB) screening for colorectal cancer within the Nottingham trial. Setting: A randomised controlled trial (1981-present) of 153,000 subjects, of whom approximately half were offered biennial FOB testing over up to five screening rounds. Methods: The additional costs of participation in screening relative to symptomatic presentation were calculated by combining the results of (i) a comprehensive audit of resource use on the part of subjects within the trial, (ii) previously-established unit costs for each of the procedures involved. life expectancy gains were estimated from a survival analysis of those trial subjects who had been diagnosed with cancer (screening participants vs controls).
M or e than 220,000 new cases of colorectal cancer are recorded annually in the European Union, making the large bowel the most common cancer site.' Tumours typically progress through a series of stages, although symptoms tend to present only when the disease is well advanced. Patient prognosis is strongly associated with the extent of progression at diagnosis and treatment. Colorectal tumours bleed intermittently and can therefore be signalled by the presence of occult blood in the stools. By hypothesis, mass population screening for faecal occult blood (FOB) could be expected to increase the chances of detection and treatment of colorectal cancers at earlier stages, thereby improving survival. ' A randomised controlled trial of FOB screening has been in progress in Nottingham, England, since 1981.3.4 Approximately 153,000 asymptomatic individuals, aged 45-74 years, were randomised into equal-sized intervention and control groups. Screening, and the treatment of screendetected cancers, was completed by the year 2000, although follow-up continues. The trial's clinical findings to date have supported the screening hypothesis. At an average of 7.8 years of follow-up, the reduction in colorectal cancer mortality in the intervention group was 15 per cent.' At 11 years of follow-up, the reduction was 13 per cent, but 27 per cent for those who had actually accepted the offer of screening."
Since the late-1980s, an economic evaluation of FOB screening has been undertaken, in parallel with the clinical trial. Estimates for cost-effectiveness have already been published? although, at the time of that analysis, screening was still in progress. These earlier estimates were derived from a Markovian model of disease progression and were intended to simulate a national programme." This type of modelling approach has become increasingly common in the economic analysis of colorectal screening.":" Whilst being informed by the trial results then available, however, our previous results were heavily-reliant on cost forecasts and projections, or on existing medical opinion with respect to, www.jmedscreen.com for example, eventual cancer yield from screening, posttreatment survival and progression rates between cancer stages. Screening having been completed, we now possess far more trial data, including full information regarding resource use and yield from screen-detection. We are therefore in a position to report trial-based estimates for the costeffectiveness of cancer detection by means of FOB screening specific to the Nottingham protocol.
METHOD
Under the Nottingham trial protocol. an FOB test kit was mailed to each of the subjects in the intervention group. The test entailed the self-collection of two stool samples per day over a number of consecutive days, and those samples returned to the trial centre were assayed. Subjects recording a positive FOB test result were invited for a clinic-based investigation and any confirmed cancers were removed surgically (surgery has remained the preferred mode of management throughout the trial). Subjects completing the initial screen, and for whom no abnormalities had been detected, were offered a re-screen after two years. Further re-screening was offered biennially, compliant subjects participating in a maximum of five screening rounds in total.
At the time of the trial's inception, Haemoccult was the favoured FOB test, and most subjects received this at the initial screen. Small sub-groups received either an alternative test, Fecatwin/Feca EIA (Feca), or both Feca and Haemoccult. Even so, it was unclear at the start of the trial whether three or six days would be the most appropriate sample collection period. Accordingly, the Haemoccult recipients in the intervention group were further randomised into sub-groups receiving either the three-day and or the six-day variant. Beyond the initial screen, the use of Feca and six-day Haemoccult was discontinued, and all subsequent testing entailed three-day Haemoccult.
Compliance at the first screening round proved lower than had been hoped and it was accordingly decided to re-invite those who had not responded to the initial invitation. These initial non-responders received a three-day Haemoccult test kit by mail, and those complying with this reinvitation were offered further re-screens as per the original protocol.
It had been envisaged originally that the investigation of positive FOB results would be via either colonoscopy or double-contrast barium enema X-ray although, as capacity and expertise developed during the trial, colonoscopy became the investigation of choice. Early trial findings attested to a high false positive rate, precipitated by the FOB test's responsiveness to certain characteristics of the subjects' diets. To reduce this rate, a regime of confirmatory re-testing of positives was initiated." Subjects whose stool samples were FOB-positive over all three days of testing proceeded to investigation as before. However, those with less-strong results were required to take a re-test after three months, following specified restrictions on their diet, and positives were sent for investigation. Negatives were offered a further re-test after an additional three months of restriction; again, positives were sent for investigation.
The cost component of the cost-effectiveness calculation is the cost of subject management occasioned by screening, additional to the costs entailed by the status quo, symptomatic presentation. This comprises the costs of all FOB tests issued to the intervention group, plus the costs of investigations generated by positive FOB results. In addition, the screen-detection of cancer enables treatment to be effected earlier, in comparison with symptomatic presentation (lead time). Under a regime of discounting, earlier treatment is more expensive than later, as determined by the lead time for treatment, the unit cost of treatment and the discount rate.
Based on an audit of resource use within the trial, the total cost of cancer detection via screening is simply the sum of the products of the numbers of subjects consuming each type of resource and the resources' unit costs. Each of the resource types -FOB test, investigation, treatment -had already been the subject of detailed cost analysis.'>" Accordingly, we employed these previous estimates, adjusted to 2002 prices using the GDP deflator, in our overall cost calculation.
Because of the large numbers involved, it was deemed infeasible to enter all subjects into the clinical trial simultaneously. Accordingly, subjects from 92 general practices in and around Nottingham were randomised by practice and practice samples were recruited sequentially over a ten-year period (1981) (1982) (1983) (1984) (1985) (1986) (1987) (1988) (1989) (1990) (1991) . Sequential entry, however, would be an artefact for our cost-effectiveness calculations, so we assumed that all the initial tests actually occurred in the same base year. The costs of up to four re-screens over a screening period of up to eight years beyond the base year were discounted at an appropriate discount rate. Likewise, re-invitation to the initial screen also occurred over a period of years, although we make the conservative assumption that it too occurred in the base year. Although a minority of the cancers detected at the beginning of the trial were actually investigated radiologically, we assumed that all investigations entailed colonoscopy, which is more costly." Earlier research had demonstrated that the treatment costs of earlyand late-stage cancer were not significantly different'", enabling use to use a common value for all treatments.
The true survival benefits from screening will only be measurable with precision at a point in the future when a substantial proportion of the trial population has died. At present, more than 70% of trial subjects remain alive." Accordingly, we measured the effectiveness of screening as Journol of Medical Screening 2004 Volume 11 Number 1 Whynes the survival advantage (expected life-year gains) following cancer detection in the group which complied with screening offers, i.e. those participating in screening. In this context, a participating subject is one who has accepted at least one FOB test offer. By 2003, more than 3300 cancers from the trial had been identified and treated, and around one-third of the patients remained alive. The majority of these cancers were the result of symptomatic presentation, either in control group subjects or in intervention group subjects who had not accepted the screening offers. The remaining cancers were from the participant group, either screen-detected or presenting symptomatically in subjects who had previously recorded one or more negative test results (interval cases).
The survival advantage attributable to screening participation was estimated in two alternative ways. First, we used a Kaplan-Meier analysis to compare the life expectancies of participating subjects with cancer with those of control subjects with cancer, survival at a recent reference date indicating censoring. Second, for those still alive at the reference date, we imputed age at death using age-and sex-specific life expectancies, as produced by the UK Government Actuary's Department. We then compared the mean actual or imputed ages at death for the participating subjects with cancer and the control cancers. These approaches to survival estimation rest on the presumption that non-participants in the intervention group -those offered screening but who failed to comply with any such offer -will have similar survival profiles to those in the control group.
We presumed that the survival advantage or benefit from participation in screening began to accrue to subjects at the end of their lives, beyond the point at which cancer-related death had occurred in the control group. This temporal delay in benefit accrual was estimated as the mean age at death of the control group cancers less the mean age at first screening for the participating-subjects' cancers. As with costs, benefits were subject to discounting. Comparison of the mean ages at detection for the screen-detected and control cancers yielded an estimate of lead time for treatment, necessary for the cost calculations.
RESULTS
At the reference date (April 2003), 945 cancers had been detected in the participant group, compared with 1691 in the control group. The mean time elapsed since trial entry for these groups combined was 16.5 years. For cancers in the participant group, 39.6% of subjects were surviving at the reference date, compared with 32.2% of the control group (X 2 = 14.41. p<O.OI). The Kaplan-Meier analysis indicated a mean survival advantage of participants over controls of 1.46 years (Confidence Interval [CI]: 0.67-2.25). This average for the participant group decomposes into 2.06 years (CI: 0.75-3.37) for the screen-detected cancers and 1.21 (CI: 0.33-2.09) for the remainder. For the participants as a whole, the median Kaplan-Meier survival advantage compared with the controls was 1.12 years (CI: 0.06-2.18), whilst the advantage as estimated on the basis of imputed age at death was 1.34 years (CI: 0.62-2.05). We use the lowest estimate in our subsequent calculations.
The lead time over controls for treatment following screen-detection was 3.32 years (CI: 2.42-4.21), although interval cancers presented, on average, at a slightly later age than control cancers (age difference = 0.78 years, CI: 0.01-1.46). This would appear to imply that interval presentation offers a discount on treatment costs compared with controls although, to err towards conservatism, we www.jmedscreen.com Cost-effectiveness of colorec:tol cancer screening ignored this effect. The difference between mean age at first screening amongst participants and the mean age at death of the control group cancers was 14.90 years (CI: 14.23-15.57). By implication, therefore, the stream of screening benefits is initiated 14.9 years after the cost stream has commenced. Table 1 displays the resource use and activity data for the various trial phases as identified earlier. This takes the form of the numbers of FOB tests issued, tests returned for development, positives requiring investigation by colonoscopy, and cancers detected by screening and treated. It should be noted that these data pertain to tests as opposed to subjects: given the absence of perfect serial compliance, many subjects received, for example, more than two tests before returning their second. Table 2 translates the resource use data into discounted costs, estimated using the appropriate unit costs for each element. The unit cost of the three-day test, updated from our earlier estimate, n was £3.29. This included the costs of the test kit, administration and return postage. Tests were developed by a nurse, with consultant advice as appropriate, at a cost of 19 pence per test returned. Re-invitations followed an identical protocol" and were costed similarly. The corresponding costs for six-day testing were £5.43 and 39 pence, respectively. Based on our earlier study." the cost of the colonoscopy examination was £187, an estimate which allows for a proportion of investigations being undertaken on an inpatient basis. Mean treatment costs'? were £4340 (CI: 3977--4702). In these estimates, costs were discounted at six per cent as recommended by the English Department of Health 18 and, on the same basis, we used a two per cent discount rate for survival benefits. The costs of the FOB testing accounted for 59.6% of the total cost of the trial programme, those of investigations accounted for 27.5%, and the remaining 12.9% of costs was attributable to the earlier treatment of screen-detected cancers.
The survival gain of 1.12 years for each of the 945 cancers emerging in the participant group translates into a total gain of 1058 life-years, or 788 when discounted at two per cent. Given the total costs (Table 2) , the incremental costeffectiveness ratio (ICER) of the programme is therefore 13 £1584. Confidence intervals for the programme's ICER, £717-£8612, were derived by Monte Carlo simulation. This required repeated replication of the ratio calculation, with all those parameters earlier associated with confidence intervals varying across their ranges.
The ICER is relatively insensitive to plausible variations in the assumed discount rate for costs: at zero, the ICER falls by 3.8% whilst, at 12% it rises by 1.5% relative to the base estimate. This is because of compensating movements in the cost sub-totals: a higher discount rate reduces the present value of costs of future screening tests but increases the premium on the earlier treatment of disease. As might be expected in view of the protracted delay in receiving benefit, the ICER is far more sensitive to variations in the discount rate for benefits. Discounting benefits at the same rate as for costs (6%) raises the ratio by 77.4% relative to the base estimate. On the other hand, when benefits are undiscounted, the ratio falls by 25.5%. If the highest Kaplan-Meier survival estimate is used in the calculations, the lCER falls by 23.3%, relative to the base estimate. When, in turn, the unit costs of the FOB test, investigation and treatment are doubled, the ICER rises by 59.6, 27.5 and 12.9%, respectively, relative to the base estimate.
DISCUSSION
Three specific conclusions can be derived from these results. First, of all the trial phases reported, those associated with Feca and with re-invitation generated the highest costs per cancer detected ( Table 2 ). In the Feca cases, the explanation lies in the relatively poor specificity of the test, which gave rise to a disproportionate number of expensive investigations relative to cancers detected. Indeed, it was the observation of the high positive rate relative to yield'? which led to the abandonment of this type of test at an early stage in the trial. Although the detection rate amongst those reinvited at the initial screen was high (Table 1) , average detection costs were driven upwards by low compliance: around 90 per cent of the tests distributed to subjects were not returned for processing. It accordingly seems probable that the estimated cost per detection for the trial as a whole is higher than that which might have resulted had the protocol entailed three-day Haemoccult only and without re-invitation. Second, there is no evidence of increasing costs per detection as the number of tests taken increases. If anything, the reverse is the case, given that the costs per detection for the fourth and fifth test are the lowest estimated (Table 2) . In some degree, this result is to be expected because subjects completing more tests will be older, other things remaining equal, and disease incidence is known to be age-related. Cost per person screened falls over test rounds as compliance by round increases.
Finally, and possibly most importantly, the present ICER calculation is based on trial evidence, rather than on the combination of evidence and modelling as was our earlier estimate. As it transpires, the new ICER is towards the lower end of the range previously derived." Unsurprisingly, the conclusion to the present study can remain much the same as that of the earlier one. The incremental cost-effectiveness ratio for FOB screening in the Nottingham trial is lower than the equivalent ratio for the national breast cancer screening programmev-" and the estimate places Nottingham FOB screening well up the 'league table' of cost-effective interventions more generally.
One unexpected result from the analysis is that the postdetection survival gains from screening do not accrue only to those whose cancers are screen-detected, but extend to participants more generally. There is no evidence of significant differences in stage distribution or gender composition between the interval and control sub-groups, and we offer three conjectures to explain this result.
First, although this analysis has been confined to cancer, screening led to the identification of around 330 more adenomas in the participation group than in the control group, over the screening period. The majority of adenomas (59%) in the participation group were screen-detected. All adenomas were excised during colonoscopic investigation at no additional cost. According to the well-accepted adenomacarcinoma sequence." adenomas are pre-cursors to cancers. The detection and excision of these additional adenomas should therefore have prevented at least some cancers in the participant group from occurring. The later presentation of interval cancers might therefore be due to the prevention of cancers which would otherwise have presented earlier. Other studies have already reported lower cancer incidence following adenoma excision.Pv" and adenoma follow-up in Nottingham suggests a low risk of post-excision recurrence." Second, we have evidence that compliance with FOB screening was not independent of socio-economic class." More specifically, subjects from higher classes were more likely to participate. Such a finding is not surprising: it has also been observed in the recent UK trial of colorectal cancer screening by means of flexible sigmoidoscopy." and appears true for other forms of cancer screening.v" Moreover, postdiagnosis survival for all cancers seems to be inferior in areas of higher socio-economic deprivation." In comparison with controls, therefore, better outcomes could be predicted for the participant group by virtue of its class basis. Independently of screening, a disproportionate representation of higher socio-economic classes should, of itself, lead to disproportionately-favourable outcomes. Finally, we conjecture that subjects who had actively participated in screening to some degree would be better informed and more familiar with the disease's signs and symptoms than would the controls. In consequence, when cancer symptoms presented, they would be less inclined to delay seeking Journol of Medicol Screening 2004 Volume 11 Number 1 Whynes medical assistance. As with most conditions, earlier treatment could imply superior prognoses.
In the population as a whole, it is important to appreciate that the most common cancer still remains relatively uncommon: colorectal cancer incidence is below 0.5%, even in the most elderly age-groups. Most of the resources in the screening trial will therefore have been expended on subjects who did not have, nor ever would have had, colorectal cancer. The sensitivity of the FOB test appears to be of the order of 50%,31·33 whilst screening compliance has averaged less than 60%. Projecting these findings to the national level, it would follow that, amongst the minority of the population with colorectal cancer, slightly more than half may accept a screening test which will be successful in detecting perhaps half of those cancers present. It is therefore inevitable that the survival gains from participation in colorectal cancer screening will accrue only to a minority of individuals. In the Nottingham case, this number is equivalent to 1.2 % of those initially invited for screening (intervention group). The average survival gain resulting from participating in screening translates to an average gain of just 8.7 days (undiscounted) per subject accepting one or more FOB test offers.
It is improbable that such a minuscule average survival gain would ever be discernible at a population level, and the same would probably continue to be true were test sensitivity and compliance to be higher. A recent commentary expressing concern for the lack of evidence for aggregate survival improvements following the increasing uptake of colorectal screening in the USA should be viewed in this light." This, however, is not really the point. A large and widespread survival gain is neither a necessary nor a sufficient condition for value-for-money. The Nottingham trial data indicate that. although the number of cases detected by screening was relatively modest in relation to the number of subjects invited, the combination of the survival gains accruing to those participating in screening and the costs of the programme were sufficient to yield a low cost-effectiveness ratio overall.
